Protalix BioTherapeutics Return on Equity

Protalix BioTherapeutics (PLX) currently reports a ROE of 26.53%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore Protalix BioTherapeutics's ROE history and peer comparisons.

Protalix BioTherapeutics's ROE of 26.53% is higher than the Healthcare sector average of 20.77%. That is roughly 27.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Protalix BioTherapeutics's current 26.53% should be judged against Healthcare norms (sector average: 20.77%) and against PLX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 26.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Protalix BioTherapeutics, and consider following PLX for alerts when major investors trade the stock.

Protalix BioTherapeutics is classified in the Healthcare sector. On ROE, it currently shows 26.53% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLX with unrelated industries.